Concepedia

Eftychia Koumarianou

EK

Statistics

Publications

15

Citations

804

H-Index

14

Active since

2009

Affiliations

Duke Medical Center(Current)

Duke University Hospital

Duke University

National Centre for Nuclear Research

Ablynx (Belgium)

Eftychia Koumarianou is an author at Duke Medical Center specializing in medicine, molecular oncology, and oncology.

ORCID

Publications per year

2009–2019

15

Publications

15

(2<i>S</i>)-2-(3-(1-Carboxy-5-(4-<sup>211</sup>At-Astatobenzamido)Pentyl)Ureido)-Pentanedioic Acid for PSMA-Targeted α-Particle Radiopharmaceutical Therapy

Ana P. Kiess, Il Minn, Ganesan Vaidyanathan et al. · Journal of Nuclear Medicine · 2016 · 139 citations · Full text

, , +17

Targeting breast carcinoma with radioiodinated anti-HER2 Nanobody

Marek Pruszyński, Eftychia Koumarianou, Ganesan Vaidyanathan et al. · Nuclear Medicine and Biology · 2012 · 107 citations · Full text

, , +14

Preclinical Evaluation of <sup>18</sup>F-Labeled Anti-HER2 Nanobody Conjugates for Imaging HER2 Receptor Expression by Immuno-PET

Ganesan Vaidyanathan, Darryl McDougald, Jae‐Yeon Choi et al. · Journal of Nuclear Medicine · 2016 · 91 citations · Full text

, , +17

Improved Tumor Targeting of Anti-HER2 Nanobody Through <i>N</i>-Succinimidyl 4-Guanidinomethyl-3-Iodobenzoate Radiolabeling

Marek Pruszyński, Eftychia Koumarianou, Ganesan Vaidyanathan et al. · Journal of Nuclear Medicine · 2014 · 88 citations · Full text

, , +17

Astatine-211 labeled anti-HER2 5F7 single domain antibody fragment conjugates: radiolabeling and preliminary evaluation

Jae‐Yeon Choi, Ganesan Vaidyanathan, Eftychia Koumarianou et al. · Nuclear Medicine and Biology · 2017 · 82 citations · Full text

, , +16

1–5 of 15